Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon plans to submit information to FDA within “the next few weeks.”
You may also be interested in...
Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil
FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.
Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil
FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.